Press "Enter" to skip to content

Roche’s combo lymphoma treatment wins U.S. FDA approval

Polivy was approved in combination with Roche’s older drug Rituxan and a chemotherapy agent for adult patients with advanced diffuse large B-cell lymphoma (DLBCL) whose cancer has worsened despite at least two previous lines of therapy.

Original source:

Also Read:   High-cost Gilead cell therapy proves durable for some lymphoma patients